Orbimed Advisors LLC Decreases Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Orbimed Advisors LLC decreased its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 49.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,103,623 shares of the company's stock after selling 2,982,378 shares during the period. Orbimed Advisors LLC owned about 1.06% of Lyell Immunopharma worth $1,986,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Decheng Capital LLC acquired a new stake in shares of Lyell Immunopharma during the fourth quarter valued at about $7,622,000. Foresite Capital Management V LLC acquired a new stake in Lyell Immunopharma during the 4th quarter valued at approximately $5,205,000. Geode Capital Management LLC increased its holdings in Lyell Immunopharma by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company's stock worth $2,648,000 after purchasing an additional 117,303 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Lyell Immunopharma by 43.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company's stock valued at $1,053,000 after purchasing an additional 498,417 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Lyell Immunopharma by 716.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock valued at $1,032,000 after purchasing an additional 1,414,746 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company's stock.

Insider Activity

In other news, Director Richard Klausner bought 158,000 shares of the firm's stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the transaction, the director now owns 843,365 shares in the company, valued at approximately $506,019. This trade represents a 23.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Lynn Seely purchased 175,000 shares of the business's stock in a transaction dated Friday, March 14th. The shares were acquired at an average cost of $0.61 per share, for a total transaction of $106,750.00. Following the acquisition, the chief executive officer now owns 712,500 shares of the company's stock, valued at approximately $434,625. The trade was a 32.56% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 768,640 shares of company stock valued at $449,508. 25.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "neutral" rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

Lyell Immunopharma Stock Performance

NASDAQ:LYEL opened at $0.42 on Tuesday. The company has a market capitalization of $124.51 million, a price-to-earnings ratio of -0.53 and a beta of -0.25. Lyell Immunopharma, Inc. has a one year low of $0.39 and a one year high of $2.88. The stock has a 50-day simple moving average of $0.50 and a 200 day simple moving average of $0.67.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million during the quarter. On average, equities research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.